EVOKE PHARMA INC (EVOK) Stock Price & Overview
NASDAQ:EVOK • US30049G3020
The current stock price of EVOK is 11 USD. Today EVOK is up by 0.36%. In the past month the price increased by 2.9%. In the past year, price increased by 116.96%.
EVOK Key Statistics
- Market Cap
- 18.92M
- P/E
- N/A
- Fwd P/E
- 15.86
- EPS (TTM)
- -2.21
- Dividend Yield
- N/A
EVOK Stock Performance
EVOK Stock Chart
EVOK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to EVOK. When comparing the yearly performance of all stocks, EVOK is one of the better performing stocks in the market, outperforming 97.83% of all stocks.
EVOK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EVOK. EVOK has a bad profitability rating. Also its financial health evaluation is rather negative.
EVOK Earnings
On November 13, 2025 EVOK reported an EPS of -0.45 and a revenue of 4.28M. The company beat EPS expectations (1.96% surprise) and missed revenue expectations (-2.92% surprise).
EVOK Forecast & Estimates
6 analysts have analysed EVOK and the average price target is 18.36 USD. This implies a price increase of 66.91% is expected in the next year compared to the current price of 11.
For the next year, analysts expect an EPS growth of 57.76% and a revenue growth 59.35% for EVOK
EVOK Groups
Sector & Classification
EVOK Financial Highlights
Over the last trailing twelve months EVOK reported a non-GAAP Earnings per Share(EPS) of -2.21. The EPS increased by 79.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.4% | ||
| ROE | -155.44% | ||
| Debt/Equity | 1.49 |
EVOK Ownership
EVOK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 29.83 | 952.688B | ||
| JNJ | JOHNSON & JOHNSON | 21.05 | 594.495B | ||
| MRK | MERCK & CO. INC. | 22.28 | 297.42B | ||
| PFE | PFIZER INC | 8.86 | 151.126B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.24 | 124.629B | ||
| ZTS | ZOETIS INC | 18.45 | 55.496B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.16 | 27.407B | ||
| VTRS | VIATRIS INC | 5.91 | 17.144B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.69 | 12.37B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.391B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.298B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 4.453B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.408B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EVOK
Company Profile
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 3 full-time employees. The company went IPO on 2013-09-25. The company develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. The company has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Company Info
EVOKE PHARMA INC
420 Stevens Avenue, Suite 230
Solana Beach CALIFORNIA 92075 US
CEO: David A. Gonyer
Employees: 3
Phone: 18583451494
EVOKE PHARMA INC / EVOK FAQ
Can you describe the business of EVOKE PHARMA INC?
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 3 full-time employees. The company went IPO on 2013-09-25. The company develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. The company has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Can you provide the latest stock price for EVOKE PHARMA INC?
The current stock price of EVOK is 11 USD. The price increased by 0.36% in the last trading session.
What is the dividend status of EVOKE PHARMA INC?
EVOK does not pay a dividend.
How is the ChartMill rating for EVOKE PHARMA INC?
EVOK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does EVOKE PHARMA INC have?
EVOKE PHARMA INC (EVOK) currently has 3 employees.
Can you provide the market cap for EVOKE PHARMA INC?
EVOKE PHARMA INC (EVOK) has a market capitalization of 18.92M USD. This makes EVOK a Nano Cap stock.
Can you provide the ownership details for EVOK stock?
You can find the ownership structure of EVOKE PHARMA INC (EVOK) on the Ownership tab.